Format

Send to

Choose Destination
Int J Risk Saf Med. 2015;27(2):85-91. doi: 10.3233/JRS-150645.

Suicidal risk from TADS study was higher than it first appeared.

Author information

1
Department of Women's and Children's Health, Child and Adolescent Psychiatric Unit, Karolinska Institutet, Astrid Lindgren Children's Hospital, Stockholm, Sweden.
2
Stockholm Child and Adolescent Psychiatry, BUP Huddinge, Stockholm, Sweden.
3
Department of Psychiatry and Behavioral Sciences, University of Nevada School of Medicine, Reno, NV, USA.
4
Bangor University, Wales, UK.

Abstract

Completed suicides are a major cause of death in adolescents in Sweden. Forensic analysis of completed suicides in children and adolescents shows there is one completed suicide per 1000 children taking a selective serotonin re-uptake inhibitor (SSRI). In order to elucidate these events we undertook a study of the results and reporting of suicidal events in the Treatment of Adolescents with Depression Study (TADS). We conclude that a major, albeit underreported, finding in the TADS was the significant increase of suicidal events in the adolescents on antidepressant medication in comparison to the group on placebo medication. The proportions of suicidal events were 11% and 2.7% respectively. This increased risk of suicidal events might be related to the high incidence of medication with an SSRI in the group of completed suicides among Swedish adolescents.

KEYWORDS:

CBT; SSRIs; TADS; adolescent depression; suicide

PMID:
26410011
DOI:
10.3233/JRS-150645
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center